Zymeworks (ZYME) Posts Revs of $1.3M

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Zymeworks (ZYME) Posts Revs of $1.3M

Zymeworks Reports Second Quarter 2017 Financial Results

August 8, 2017 4:01 PM EDT

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (Zymeworks) (NYSE: ZYME; TSX: ZYME) a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer, today reported financial results for the second quarter ended June 30, 2017.

During the second quarter, in addition to the completion of our initial public offering, we made significant progress on our clinical and partnered programs, said Ali Tehrani, Ph.D., Zymeworks President & CEO. We presented detailed dose escalation data at ASCO demonstrating safety and anti-tumor activity for ZW25. We also announced progress... More